Indications: LYBALVI® is indicated for the treatment of adults with schizophrenia or bipolar I disorder for acute treatment of manic or mixed episodes as monotherapy and as an adjunct to lithium or valproate, or as a maintenance monotherapy treatment.
If you have questions about LYBALVI, you can reach Alkermes through one of the following options:
REQUEST A SALES REPRESENTATIVERequest an Appointment
852 Winter Street
Waltham, MA 02451
Please include as many details as you can about your questions and how you would like us to contact you in return.
You may report a suspected adverse event related to Alkermes products by calling (888) 235-8008 (United States only) or by emailing us at email@example.com.You are encouraged to report all side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call